Abstract
Novel pivotal trial designs, that more clearly demonstrate increased benefit over Standard of Care (SOC), especially in oncology and immuno-oncology (IO) are presented. The benefit of therapy is maximized and sample size is dramatically reduced. The novel methodology includes the introduction of a biochemical “Optimizing Diagnostic”, for example a cfDNA test that can detect poor response, when performed early after therapy is begun; this is used to change the therapy of the tested person early in the trial (typically to SOC), before clinical progression. Patients remain in “the new drug first” group, which is compared to SOC. An “Optimizing Diagnostic” is analogous to a “Companion Diagnostic”, both potentially allow approval of drugs that would otherwise fail. A companion diagnostic predicts benefit prior to therapy, the optimizing diagnostic (more accurately) predicts likelihood of benefit after initial therapy. Those patients deemed less likely to respond, remain in the novel drug first arm, but are switched to SOC. A Sequential Multiple Assignment Randomized Trial” (SMART) design is proposed to evaluate if switching to SOC or SOC plus continuing the novel therapy is most beneficial. These designs will allow approval of therapy paths including novel agents when the novel agent could not be approved without this design. A good optimizing test may reduce the number of patients needed by 80%, dramatically reducing cost and time; more patients benefit and accrual is easier.
Key Points
A new clinical trial design focused on testing a path that begins with a novel regimen (IO is featured) is presented.
The path includes an “optimizing diagnostic” that determines, early during treatment, if a patient should remain on the new regimen.
Companion diagnostics define the path at a pre-treatment stage, optimizing diagnostics define the path early during treatment. Changes in therapy, typically to the SOC, is made based on the post-test probability of success.
The novel path is significantly more likely to lead to approval than the novel regimen alone.
Use of the novel method can reduce the size of a trial by 80%, and allow approval of the path, when approval of the novel regimen, based on a head-to-head trial vs SOC, would not be possible.
Competing Interest Statement
Floyd Taub is CEO of aiGENE, Inc. a company doing R&D on a cfDNA methodology.
Funding Statement
This study did not receive any funding, however Dr. Taub is an employee of aiGENE, Inc.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
